BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sultana F, Manasa KL, Shaik SP, Bonam SR, Kamal A. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Curr Med Chem 2019;26:7212-80. [PMID: 29852860 DOI: 10.2174/0929867325666180530094120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Semin Cancer Biol 2020:S1044-579X(20)30176-0. [PMID: 32814115 DOI: 10.1016/j.semcancer.2020.07.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
2 Lee HS, Kim SH, Kim BM, Safe S, Lee SO. Broussochalcone A Is a Novel Inhibitor of the Orphan Nuclear Receptor NR4A1 and Induces Apoptosis in Pancreatic Cancer Cells. Molecules 2021;26:2316. [PMID: 33923503 DOI: 10.3390/molecules26082316] [Reference Citation Analysis]
3 Abu-Hashem AA, Al-Hussain SA, Zaki MEA. Design, Synthesis and Anticancer Activity of New Polycyclic: Imidazole, Thiazine, Oxathiine, Pyrrolo-Quinoxaline and Thienotriazolopyrimidine Derivatives. Molecules 2021;26:2031. [PMID: 33918322 DOI: 10.3390/molecules26072031] [Reference Citation Analysis]
4 Körholz K, Ridinger J, Krunic D, Najafi S, Gerloff XF, Frese K, Meder B, Peterziel H, Vega-Rubin-de-Celis S, Witt O, Oehme I. Broad-Spectrum HDAC Inhibitors Promote Autophagy through FOXO Transcription Factors in Neuroblastoma. Cells 2021;10:1001. [PMID: 33923163 DOI: 10.3390/cells10051001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rock A, Ali S, Chow WA. Systemic Therapy for Chondrosarcoma. Curr Treat Options Oncol 2022. [PMID: 35190971 DOI: 10.1007/s11864-022-00951-7] [Reference Citation Analysis]
6 Hassell KN. Histone Deacetylases and their Inhibitors in Cancer Epigenetics. Diseases 2019;7:E57. [PMID: 31683808 DOI: 10.3390/diseases7040057] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
7 Asawa RR, Zakharov A, Niehoff T, Chitsaz A, Jadhav A, Henderson MJ, Simeonov A, Martinez NJ. A Comparative Study of Target Engagement Assays for HDAC1 Inhibitor Profiling. SLAS Discov 2020;25:253-64. [PMID: 31662025 DOI: 10.1177/2472555219883625] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Schmitz RL, Weissbach J, Kleilein J, Bell J, Hüttelmaier S, Viol F, Clauditz T, Grabowski P, Laumen H, Rosendahl J, Michl P, Schrader J, Krug S. Targeting HDACs in Pancreatic Neuroendocrine Tumor Models. Cells 2021;10:1408. [PMID: 34204116 DOI: 10.3390/cells10061408] [Reference Citation Analysis]
9 Müller M, Rösch L, Najafi S, Gatzweiler C, Ridinger J, Gerloff XF, Jones DTW, Baßler J, Kreth S, Stainczyk S, Frese K, Meder B, Westermann F, Milde T, Peterziel H, Witt O, Oehme I. Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers (Basel) 2021;13:4476. [PMID: 34503286 DOI: 10.3390/cancers13174476] [Reference Citation Analysis]